• Explore /
  • Poster
  • / 19-BI-1808-01, a phase 1/2a clinical trial of BI-1808, a tumor necrosis factor receptor 2 (TNFR2) blocker/depleter with or without pembrolizumab.

19-BI-1808-01, a phase 1/2a clinical trial of BI-1808, a tumor necrosis factor receptor 2 (TNFR2) blocker/depleter with or without pembrolizumab.

Abstract Video & Slides Poster

Authors

Kristoffer Staal Rohrberg

Kristoffer Staal Rohrberg

Department of Oncology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark

Kristoffer Staal Rohrberg , Zsuzsanna Papai , Rikke Løvendahl Eefsen , Jeffrey Yachnin , Ana Carneiro , Sean H Lim , Harriet S. Walter , Istvan Lang , Edvard Abel , Kirstie Cleary , Mark Cragg , Robert Oldham , Marie Borggren , Susanne Gertsson , Ingrid Karlsson , Johan Erik Wallin , Michael Jon Chisamore , Ingrid Teige , Björn Frendeus , Andres McAllister

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Other Checkpoint Inhibitors (Non-PD1/PDL1, Monotherapy, or Combination)

Clinical Trial Registration Number

NCT04752826

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 2641)

DOI

10.1200/JCO.2024.42.16_suppl.2641

Abstract #

2641

Poster Bd #

120

Abstract Disclosures

Similar Posters

First Author: Marcus Smith Noel

First Author: Minal A. Barve

First Author: Benjamin Philip Levy

First Author: Anthony W. Tolcher